An Australian stem cell and regenerative medicine company


Dr Ross Macdonald

Managing Director and Chief Executive Officer

Dr Macdonald has over 20 years’ experience and a track record of success in pharmaceutical and biotechnology businesses. His career history includes positions as Chief Executive Officer of Hatchtech Pty Ltd, Vice President of Business Development for Sinclair Pharmaceuticals Ltd, a UK-based specialty pharmaceuticals company, Vice President of Business Development for Connetics Corporation (Palo Alto, CA), and Vice President, Corporate Development for Stiefel Laboratories Inc, the largest independent dermatology company in the world and acquired by Glaxo Smith Kline in 2009 for £2.25b. Dr Macdonald has also served as Vice President of Research and Development of F H Faulding & Co Ltd and CEO of Living Cell Technologies Ltd.  His other positions have included non-executive director roles at iSonea Ltd, Telesso Technologies Ltd, Hatchtech Pty Ltd and Relevare Pharmaceuticals Ltd. Dr Macdonald currently serves as a member of the Investment Committee of UniSeed Management Pty Ltd. Dr Macdonald holds a PhD in Biochemistry, Monash University, a Graduate Diploma in Business Administration, Swinburne University, and he is a member of the Licensing Executives Society.

Dr Kilian Kelly

Chief Operating Officer

Dr Kilian Kelly has over 15 years’ experience in biopharmaceutical research and development. His previous appointments include Senior Director, Drug Development at Biota Pharmaceuticals (NASDAQ: BOTA), Vice President, Regulatory and Clinical at Mesoblast Limited (ASX:MSB), and positions with Kendle International (now Syneos Health; NASDAQ: SYNH), Amgen (NASDAQ: AMGN) and AstraZeneca (LSE: AZN). Dr Kelly holds a Masters in Pharmacy from Robert Gordon University, Aberdeen and a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow. He is a registered pharmacist and a member of the Royal Pharmaceutical Society, the Australian Institute of Company Directors, the Organisation for Professionals in Regulatory Affairs and the International Society for Cell and Gene Therapy. He also currently serves on the Industry Interface Committee of the Center for Commercialisation of Regenerative Medicine (CCRM) Australia.

Dr Suzanne Lipe

Vice President, Partner Engagement

Dr Suzanne Lipe has over 25 years’ experience in the pharmaceutical and biotechnology industry, with key roles including research and development, in commercial and academic settings. Her previous appointments include Vice President, Operations at Mesoblast Limited (ASX:MSB), CEO Prota Therapeutics, Chief Operating Officer Norwood Immunology (AIM: NIM), various senior sales and marketing roles with CSL (ASX: CSL) and head of regulatory affairs and clinical research with Rhone-Poulenc Rorer (later becoming Aventis) and other regulatory roles at ICI Australia (later becoming AstraZeneca) and IDT (ASX:IDT). Dr Lipe holds a PhD in Pharmacology and a Bachelor of Laws Degree, at the University of Melbourne and was admitted to practice law in the Victorian Supreme Court.

Dr Jolanta Airey

Chief Medical Officer

Dr Airey is an accomplished biopharmaceutical executive and physician with broad international experience in the successful development and commercialisation of pharmaceutical products including novel biological agents. She has been involved in the design and execution of multiple clinical trials from early through to late stage, encompassing a wide range of therapeutic categories in multiple geographies. Dr Airey is expected to join Cynata in October from CSL Limited where she is currently Director, Translational Development. Previously Dr Airey was a Clinical Development Physician at Seqirus, a CSL company, and earlier held a range of medical positions within biotech, pharmaceutical and clinical research companies. Her career path has led to her playing important roles in the market approvals of several drug products.